Process for alleviating proliferative skin diseases

• US 4,007,268 A
• Filed: 05/22/1975
• Issued: 02/08/1977
• Est. Priority Date: 01/16/1973
• Status: Expired due to Term

• Current Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Original Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Inventors: Voorhees, John J.
• Primary Examiner(s): Rosen, Sam
• Application Number:
  US05/580,014
• Time in Patent Office: 628 Days
• Field of Search: 424/200
• US Class Current: 514/81
• CPC Class Codes: C07H 19/20 with the saccharide radical esterified by phosphoric or polyphosphoric acids

Abstract

A process and pharmaceutical composition for alleviating proliferative skin diseases such as psoriasis, atopic dermatitis, etc., comprising administering to humans, or domesticated animals, topically, and/or parenterally, and/or systemically a composition comprising a pharmaceutical carrier and at least one active compound selected from c-AMP analogs and antiviral agents.

Claims

1. A process for treating proliferating skin diseases which comprises administering to the afflicted human or animal, a composition containing as an active component at least one of the compounds selected from the groups:

I. A compound of the formula ##STR5## wherein R₁ is H or methyl;

R₂ is H or phenyl;

R₃ is propyl, isopropyl or phenyl;

R₄ is H, bromine, methylthio, or benzylthio;

X is oxygen or methylene;

Ii. a compound of the formula ##STR6## wherein R₁ and R₂ are hydrogen or hydroxyl;

Y is hydrogen or alkali metal;

Z is hydrogen, benzylthio, thiol, halogen, alkylthio wherein alkyl is from 1 to 8 carbon atoms, inclusive, and hydroxy;

R₄ is hydrogen, ##STR7## wherein R₅ is phenyl, benzyl or alkyl of 1 to 8 carbon atoms;

III. A compound of the formula ##STR8## wherein R₁ is --CONH₂, --CSNH₂, --C(NH)NH₂, --C(NH)NHOH, --CN, or --COOCH₃ ;

R₁ and R₂ are hydrogen or hydroxy;

Y is hydrogen or alkali metal, said compounds being in association with a pharmaceutical carrier wherein the concentration of said active component is effective to alleviate a proliferative skin disease.

2. A process in accordance with claim 1 wherein the said active compound is at least one compound having the formula ##STR9## wherein R₁ is H or methyl;

R₂ is H or phenyl;

R₃ is propyl, isopropyl or phenyl;

R₄ is H, bromine, methylthio, or benzylthio;

X is oxygen or methylene.

3. A process in accordance with claim 1 wherein the said active compound is at least one compound having the formula ##STR10## wherein R₁ and R₂ are hydrogen or hydroxyl;

Y is hydrogen or alkali metal;

Z is hydrogen, benzylthio, thiol, halogen, alkylthio wherein alkyl is from 1 to 8 carbon atoms, inclusive, and hydroxy;

R₄ is hydrogen, ##STR11## wherein R₅ is phenyl, benzyl or alkyl of 1 to 8 carbon atoms.

4. A process in accordance with claim 1 wherein the said active compound is at least one compound having the formula ##STR12## wherein R₁ is --COHN₂, --CSNH₂, --C(NH)NH₂, --C(NH)NHOH, --CN, or --COOCH₃ ;

R₁ and R₂ are hydrogen or hydroxy;

Y is hydrogen or alkali metal, said compounds being in association with a pharmaceutical carrier wherein the concentration of said active component is effective to alleviate a proliferative skin disease.